CCP
ASND icon

Clough Capital Partners’s Ascendis Pharma A/S ASND Stock Holding History

Clough Capital Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-51,200
Closed -$4.57M – 205
2023
Q2 		$4.57M Buy
+51,200
New +$4.46M 0.46% 68

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Clough Capital Partners's ASND Position: Q3 2023 in Review

Clough Capital Partners sold out of Ascendis Pharma A/S (ASND) in Q3 2023, closing a stake of 51,200 shares — an estimated $4.57M sold.

Clough Capital Partners first reported a position in ASND in Q2 2023 and held it in 1 quarter. The position peaked at $4.57M in Q2 2023. 160 funds tracked by Wall St. Rank hold ASND as of Q3 2023.

  • Clough Capital Partners reported no remaining Ascendis Pharma A/S position as of Q3 2023 after selling out during the quarter.
  • Clough Capital Partners sold 51,200 Ascendis Pharma A/S shares in Q3 2023, an estimated $4.57M.
  • Clough Capital Partners first reported a position in Ascendis Pharma A/S in Q2 2023 and held it in 1 quarter.
  • Clough Capital Partners's Ascendis Pharma A/S position peaked at $4.57M in Q2 2023.
  • 160 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2023.

Based on Clough Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.